Last reviewed · How we verify
β-lactams or ciprofloxacin
β-lactams inhibit bacterial cell wall synthesis by binding penicillin-binding proteins, while ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV to prevent DNA replication.
β-lactams inhibit bacterial cell wall synthesis by binding penicillin-binding proteins, while ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV to prevent DNA replication. Used for Bacterial infections susceptible to β-lactams (e.g., pneumonia, urinary tract infections, skin infections), Bacterial infections susceptible to ciprofloxacin (e.g., respiratory tract infections, urinary tract infections, gastrointestinal infections).
At a glance
| Generic name | β-lactams or ciprofloxacin |
|---|---|
| Also known as | Cephalosporins or ciprofloxacin or penicillincs |
| Sponsor | University of Athens |
| Drug class | Antibiotic (β-lactam and fluoroquinolone) |
| Target | Penicillin-binding proteins (β-lactams); DNA gyrase and topoisomerase IV (ciprofloxacin) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
β-lactams are bactericidal agents that disrupt peptidoglycan cross-linking in the bacterial cell wall, leading to cell lysis and death. Ciprofloxacin is a fluoroquinolone that inhibits essential bacterial enzymes required for DNA replication and transcription. These are distinct antibiotic classes with different mechanisms, often used for different bacterial infections or sometimes in combination for broader coverage.
Approved indications
- Bacterial infections susceptible to β-lactams (e.g., pneumonia, urinary tract infections, skin infections)
- Bacterial infections susceptible to ciprofloxacin (e.g., respiratory tract infections, urinary tract infections, gastrointestinal infections)
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea, vomiting)
- Allergic reactions (rash, urticaria)
- Tendinopathy (ciprofloxacin)
- QT prolongation (ciprofloxacin)
- Photosensitivity (ciprofloxacin)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- β-lactams or ciprofloxacin CI brief — competitive landscape report
- β-lactams or ciprofloxacin updates RSS · CI watch RSS
- University of Athens portfolio CI